A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

NCT00724334 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb